LEADER 03572nam  22005535  450 
001 9910337526103321
005 20200705122821.0
010   $a3-030-02976-X
024 7 $a10.1007/978-3-030-02976-0
035   $a(CKB)4100000007610990
035   $a(DE-He213)978-3-030-02976-0
035   $a(MiAaPQ)EBC5702836
035   $a(PPN)235005487
035   $a(EXLCZ)994100000007610990
100   $a20190211d2019      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPlacebos and Nocebos in Headaches /$fedited by Dimos D. Mitsikostas, Fabrizio Benedetti
205   $a1st ed. 2019.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019.
215   $a1 online resource (IX, 142 p. 5 illus., 3 illus. in color.) 
225 1 $aHeadache,$x2197-652X
311   $a3-030-02975-1 
327   $a1 Headache Classification and Diagnosis -- 2 The burden of headache -- 3 Patient centred approach in headaches -- 4 Unmet needs in headache management -- 5 Mechanisms of pain and headache -- 6 The reward system -- 7 Mechanisms of placebo -- 8 Mechanisms of nocebo -- 9 Placebo in headache treatment -- 10 Nocebo in headache treatment. .
330   $aThis book discusses the role of placebos and nocebos in the treatment of headache disorders. These disorders are usually treatable, but safety and tolerability issues mean that available preventive treatments have often limited success, even in the right hands ? one in five patients treated with a migraine preventive pharmaceutical agent discontinues treatment for those reasons. The nocebo effect plays a role here, with patients? negative expectation and previous unpleasant treatment experiences creating negative belief in the treatment?s benefits and safety, which in turn limits treatment outcomes and adherence significantly. In RCTs on migraine prevention, one in 20 patients treated with a placebo discontinued treatment because of adverse events, indicating a considerable nocebo effect; the fewer potential adverse events described in the consent form, the smaller the nocebo effect. As such, physicians treating headache sufferers should acknowledge nocebo as a significant cofactor for treatment adherence and failure, and plan techniques to limit the effects, such as patient education and close follow-up. This highly informative and painstakingly presented book provides scientific insights for professionals and scholars with an interest in internal medicine, neurology and pain medicine. .
410  0$aHeadache,$x2197-652X
606   $aInternal medicine
606   $aNeurology 
606   $aPain medicine
606   $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002
606   $aNeurology$3https://scigraph.springernature.com/ontologies/product-market-codes/H36001
606   $aPain Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H47003
615  0$aInternal medicine.
615  0$aNeurology .
615  0$aPain medicine.
615 14$aInternal Medicine.
615 24$aNeurology.
615 24$aPain Medicine.
676   $a616
676   $a616.8491
702   $aMitsikostas$b Dimos D$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aBenedetti$b Fabrizio$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910337526103321
996   $aPlacebos and Nocebos in Headaches$91742356
997   $aUNINA